Application of different drugs combined with Ropivacaine in thoracic paravertebral nerve block in Ivor-Lewis radical resection of esophageal cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400087940

Enrollment

Unknown

Registered

2024-08-07

Start date

2022-01-05

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative analgesia

Interventions

group C: 0.375% ropivacaine 20ml

group D :(0.375% ropivacaine with 1 µg/kg dexmedetomidine in a total of 20 ml)

group S: 0.375% ropivacaine with 0.5ug/ml sufentanil in a total of 20 ml

group E:(0.375% ropivacaine with 1 µg/kg dexamethasone in a total of 20 ml)

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Gender is not limited, age 30 ~ 65 years old; (2) BMI 18-28kg /m2; (3) ASA is divided into ? ~ ? grades; (4) Proposed surgery: Ivor-Lewis radical surgery for esophageal cancer

Exclusion criteria

Exclusion criteria: (1) Known allergy to the test drug; (2) Coagulation dysfunction; (3) Puncture site infection; (4) Recent history of painkiller intake and drug abuse; (5) suffering from mental disorders and other diseases;

Design outcomes

Primary

Measure	Time frame
visual analogue scale (VAS) pain scores;	—

Secondary

Measure	Time frame
total analgesic consumption;	—

Countries

China

Contacts

Public ContactLu Wensheng

The Second Hospital of Lanzhou University

17393107055@163.com+86 139 9315 3322

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026